於股東週年大會日期，已發行股份總數為522,177,419股股份，即賦予股東出席股東週年 大會並就會上提呈之決議案投贊成或反對票之股份總數。截至股東週年大會日期，本公 司並無持有任何庫存股（包括任何持有或存放於中央結算系統之庫存股）及任何待註銷之 購回股份，因此，該等庫存股及待註銷之購回股份並無於股東週年大會上行使投票權， 且並無該等股票決議被排除於有權出席股東大會並於會上就股東週年大會上進行投票 權。概無任何股份賦予股東權利出席股東週年大會但依上市規則第13.40條所載須放棄表 決贊成大會上提呈的決議案。任何股東就股東週年大會所提呈的任何決議案進行投票時 並無受到任何限制，且並無股東須根據上市規則就股東週年大會上提呈的任何決議案放 棄投票。概無股東於股東週年大會通函中表明其有意就股東週年大會上提呈的決議案投 反對票或放棄投票。 - 1 - 香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 3860 於二零二五年八月十五日舉行之股東週年大會之 投票 ...

FF301 致：香港交易及結算所有限公司 公司名稱: EPS創健科技集團有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03860 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底法定/註冊股本總額： HKD 10,000,000 第 1 頁 共 10 頁 v 1 ...

Financial Performance - For the year ended 31 March 2025, the Group's revenue decreased by approximately HK$100.1 million or approximately 15.5%, from approximately HK$644.6 million for the year ended 31 March 2024 to approximately HK$544.5 million[21]. - The Group recorded a profit of HK$30.4 million for the year ended 31 March 2025, compared to a loss of HK$26.5 million for the year ended 31 March 2024[21]. - The Group's revenue decreased by approximately HKD 100.1 million or 15.5% to approximately HKD 544.5 million for the fiscal year ending March 31, 2025, compared to approximately HKD 644.6 million for the previous fiscal year[26]. - The Group recorded a profit of HKD 30.4 million, a significant improvement from a loss of HKD 26.5 million in the previous fiscal year[26]. - Total comprehensive income attributable to owners of the Company was approximately HK$36.3 million for the Reporting Year, compared to a total comprehensive expense of approximately HK$22.3 million for the year ended 31 March 2024[76]. - Basic earnings per share for the year ended 31 March 2025 was approximately HK7.41 cents, compared to a basic loss per share of approximately HK4.41 cents for the year ended 31 March 2024[117]. Business Segments Performance - The Healthcare and Medicated Products Business recorded growth in both revenue and profit despite market slowdowns[22]. - The laboratory supply distribution business also experienced growth in both revenue and profit, despite challenges such as the depreciation of the Japanese yen[22]. - The Health and Medicated Food Distribution Business achieved revenue and profit growth despite market slowdowns, aided by strategic initiatives such as developing new sales channels[51]. - The IRO business maintained revenue at approximately the same level as the previous fiscal year, successfully achieving profitability when excluding other gains from the disposal of the Japan-IRO business[24]. - The In-house R&D business made steady progress in each pipeline, although overall progress fell behind the original plan, leading to a decrease in R&D expenses compared to the previous fiscal year[24]. - HCP Business recorded revenue of approximately HK$169.6 million for the Reporting Year, representing an increase of approximately 21.6% compared to approximately HK$139.5 million for the year ended 31 March 2024[58]. - The IRO Business with CRO Services and In-house R&D Business Unit recorded revenue of approximately HK$45.2 million, representing an increase of approximately 18.5% compared to approximately HK$38.1 million for the year ended 31 March 2024[70]. - The Group's garment business recorded revenue of approximately HK$329.7 million, representing a decrease of approximately 29.4% compared to approximately HK$467.0 million for the year ended 31 March 2024[72]. Strategic Initiatives - The Company has shifted its business portfolio to focus on profit-generating businesses, disposing of its Japan-IRO business and In-house R&D business during the Reporting Period[18]. - The Company aims to connect the healthcare industries of China, Japan, and the broader Asian region as a specialized trading partner[16]. - The Company is actively promoting product and business development through partnerships with startups and research institutions in China and Japan[17]. - The Group plans to strengthen and expand existing profit-generating businesses by anticipating market changes and updating product offerings[30]. - The Group aims to optimize its business portfolio by accelerating actions such as acquiring the China-IRO and HCP businesses and disposing of the Japan-IRO business[37]. - The Group is exploring new profit-generating businesses, including a partnership to enter the cosmetics sector through a minority investment made in February[38]. Operational Efficiency - The Group is committed to enhancing operational efficiency and exploring new product categories in the Laboratory Supply Distribution Business to drive growth[31]. - The Group's administrative expenses decreased by HK$14.4 million due to delays in the development progress of the In-house R&D business[76]. - Selling and distribution expenses decreased to approximately HK$35.3 million for the year ended 31 March 2025 from approximately HK$48.8 million for the year ended 31 March 2024, representing a decrease of approximately 27.7%[110]. - Research and development expenses decreased to approximately HK$18.1 million for the year ended 31 March 2025 from approximately HK$24.3 million for the year ended 31 March 2024, representing a decrease of approximately 25.5%[109]. Market Challenges - The Garment Business faced significant challenges with a notable decline in net sales due to intensified price competition and did not meet profitability expectations[26]. - The garment business faces challenges due to economic uncertainty and shifting consumer behavior, prompting a focus on cost control and operational streamlining[169]. Management and Personnel - Mr. Washikita Kenichiro joined EPS HD in April 2024, bringing over 37 years of experience in diversified business areas including apparel and medical healthcare[175]. - Mr. Miyano Tsumoru has over 34 years of experience in the domestic pharmaceutical industry in Japan, focusing on business development and marketing since joining EPS HD in January 2002[177]. - Mr. Narumi Shoichi has over 15 years of experience in pharmaceutical development and cross-border business, currently serving as deputy director of the business development office of EPS HD[181]. - Mr. Chiu Chun Tak, appointed as an executive director on November 1, 2023, has over 34 years of experience in accounting, auditing, corporate finance, and mergers and acquisitions[183]. - Ms. Du Yao, with over 13 years of experience in skincare R&D, founded Merry Plus Corporation in 2020 and BioBeaute Co., Ltd in 2024[188]. - Mr. Liang Fei has been with EPS Japan since 2004 and holds a master's degree in information engineering, contributing to the company's technological advancements[190]. - Mr. Uematsu Takahiro has over 35 years of experience in product management and investment strategy management, leading the compliance group at EPS HD since January 2002[192]. - Mr. Yan Ping was appointed as a non-executive Director effective from November 1, 2023, bringing extensive experience in the biomedical industry in the PRC[198]. - Mr. Chan Cheuk Ho has been an independent non-executive Director since July 9, 2021, and is responsible for providing independent judgment on the Group's strategy and performance[200]. Financial Position - The Group's net current assets increased to approximately HK$151.5 million as at 31 March 2025 from approximately HK$6.9 million as at 31 March 2024[124]. - The Group's current ratio increased from approximately 1.0 as at 31 March 2024 to approximately 2.9 as at 31 March 2025, mainly due to a significant decrease in current liabilities of approximately 60.9%[124]. - As of March 31, 2025, the group's debt-to-equity ratio was 0.04, compared to 0.08 as of March 31, 2024[128]. - The group has a total bank financing agreement amounting to approximately HK$7.8 million, with an unused bank financing rate of 63% as of March 31, 2025[128]. Other Information - The company has not disclosed any recent financial performance metrics or user data in the provided documents[1]. - There are no mentions of new product developments or market expansion strategies in the provided documents[1]. - The documents do not include any future outlook or performance guidance for the company[1]. - No information regarding mergers or acquisitions was found in the provided documents[1].

- 1 - 香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：3860） 截至二零二五年三月三十一日止年度之 全年業績公告 財務摘要 截至二零二五年三月三十一日止年度，本集團營運業績如下： － 截至二零二五年三月三十一日止年度錄得收益約544.5百萬港元； － 截至二零二五年三月三十一日止年度之除稅後溢利約為30.4百萬港元； － 根據520,901,458股普通股加權平均數計算，截至二零二五年三月三十一日止年度 之每股基本盈利約為7.41港仙；及 － 董事會建議派發截至二零二五年三月三十一日止年度的末期股息每股1.0港仙，惟 須於應屆股東週年大會上取得股東批准。 全年業績 EPS創健科技集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然公佈，本公司及 其附屬公司（統稱「本集團」）截至二零二五年三月三十一日止年度（「報告年度」）之綜合業 績連同上一財政年度之比較數字如下： 綜合損益表 截至二 ...

Financial Performance - The company recorded revenue of approximately HKD 346.9 million for the six months ended September 30, 2024, a decrease from HKD 357.8 million in the same period of 2023, representing a decline of about 3.3%[3] - The net profit after tax for the reporting period was approximately HKD 17.1 million, a significant recovery from a loss of HKD 8.7 million in the same period of the previous year[5] - Basic earnings per share (EPS) for the period was approximately HKD 2.83, compared to a loss per share of HKD 1.05 in the prior year[5] - The total comprehensive income for the period was HKD 16.0 million, a recovery from a comprehensive loss of HKD 9.6 million in the same period last year[7] - The total profit before tax was HKD 19,302,000, compared to a loss of HKD 8,182,000 in the same period of 2023[30][36] Revenue Breakdown - The revenue from the apparel business was HKD 244,981,000, down 10.9% from HKD 274,964,000 year-on-year[27] - The healthcare products business generated revenue of HKD 73,408,000, an increase of 12.5% from HKD 65,060,000 in the previous year[27] - The IRO and CRO services reported revenue of HKD 28,489,000, up 60.5% from HKD 17,805,000 in the same period last year[27] - The revenue from major customer A in the apparel business was HKD 148,419,000, down from HKD 154,349,000 in the previous year[41] - The apparel segment's revenue decreased by approximately HKD 30 million or 10.9%, from HKD 275 million to HKD 245 million, primarily due to reduced orders from major clients in the US and Japan[81] Cost and Expenses - Research and development expenses totaled HKD 7.4 million, while selling and distribution expenses were HKD 20.2 million, indicating a focus on maintaining operational efficiency[5] - Administrative expenses decreased from approximately HKD 32.1 million to HKD 27.6 million, a reduction of about 14.0% due to lower employee costs and legal fees[98] - The total employee cost for the six months ended September 30, 2024, was approximately HKD 26.5 million, compared to HKD 27.6 million for the same period in 2023[117] Assets and Liabilities - The company reported total assets of HKD 253.8 million as of September 30, 2024, an increase from HKD 211.9 million as of March 31, 2024[10] - Current liabilities increased to HKD 179.2 million from HKD 205.0 million, indicating a reduction in short-term financial obligations[10] - The net current assets improved significantly to HKD 74.7 million, compared to HKD 6.9 million in the previous period, showcasing better liquidity[10] - The total assets as of September 30, 2024, amounted to HKD 474,950,000, an increase from HKD 429,885,000 as of March 31, 2024[37] - The total liabilities as of September 30, 2024, were HKD 298,752,000, compared to HKD 291,703,000 as of March 31, 2024[37] Dividends and Share Capital - The company did not recommend the payment of an interim dividend for the reporting period, reflecting a conservative approach to cash management[3] - The company did not declare any interim dividends for the current period[51][52] - As of September 30, 2024, the company's issued share capital is HKD 5.2 million, divided into 522,177,419 shares with a par value of HKD 0.01 each[108] Strategic Initiatives - The company is exploring new production sources and product development to maintain profitability in the apparel business[70] - The company is pursuing innovative research in regenerative medicine and potential treatments for obesity and diabetes[67] - The company is focusing on understanding customer preferences and identifying emerging trends to design products that drive sustainable long-term growth[118] - The company is exploring new sales structures and business models to maximize profits in response to increasing demand for healthcare products in China[120] Governance and Compliance - The company has adopted corporate governance practices and has complied with all relevant codes during the reporting period, except for a deviation regarding the roles of the chairman and CEO[121] - The audit committee consists of three members, including independent non-executive directors, and has reviewed the unaudited interim results for the reporting period[128]

Financial Performance - The Group's revenue from the IRO Business with CRO Services and In-house R&D Business Unit was approximately HK$38.1 million for the Reporting Year, representing an increase of approximately 144.2% compared to HK$15.6 million for the year ended March 31, 2023[22]. - The Group's gross loss in the IRO segment decreased to approximately HK$0.08 million from approximately HK$6.1 million for the year ended March 31, 2023, indicating improved operational efficiency[22]. - The Group's total comprehensive expenses attributable to owners for the Reporting Year were approximately HK$22.3 million, a decrease from approximately HK$45.4 million for the year ended March 31, 2023, primarily due to increased profits in the health products business[26]. - Revenue from womenswear products increased by approximately HK$39.8 million or 13.3% to approximately HK$338.6 million for the Reporting Year from approximately HK$298.8 million for the year ended 31 March 2023, driven by an increase in sales volume from approximately 3.3 million pieces to approximately 4.0 million pieces[31]. - Revenue from menswear products increased by approximately HK$48.8 million or 70.7% to approximately HK$117.8 million for the Reporting Year from approximately HK$69.0 million for the year ended 31 March 2023, attributed to an increase in sales quantity from approximately 1.0 million pieces to approximately 1.5 million pieces[62]. - Revenue from kidswear products decreased by approximately HK$3.2 million or 23.4% to approximately HK$10.5 million for the Reporting Year from approximately HK$13.7 million for the year ended 31 March 2023, due to a decrease in sales volume from approximately 0.3 million pieces to approximately 0.2 million pieces[34]. - Revenue from the Healthcare Products Business increased by approximately HK$83.7 million or 150.0% to approximately HK$139.5 million for the year ended 31 March 2024 from approximately HK$55.8 million for the year ended 31 March 2023, primarily due to the acquisition of R&E and its subsidiary[36]. - Other income, gains and losses increased by approximately HK$12.2 million to a gain of HK$11.9 million for the year ended 31 March 2024 from a loss of approximately HK$0.3 million for the year ended 31 March 2023, mainly due to a fair value gain on promissory note of approximately HK$16.1 million related to the acquisition of 65% equity interests in R&E[39]. - Selling and distribution expenses increased by approximately HK$15.0 million or 44.4% to approximately HK$48.8 million for the year ended 31 March 2024 from approximately HK$33.8 million for the year ended 31 March 2023, attributed to increased transportation costs and selling expenses[40]. - The Group's gross profit improved to approximately HK$69.7 million for the Reporting Year, representing an increase of approximately 12.8% compared to approximately HK$61.8 million for the year ended 31 March 2023[94]. - The gross profit margin decreased to approximately 14.9% for the Reporting Year from approximately 16.2% for the year ended 31 March 2023, mainly due to a decrease in average selling price per piece[94]. - The gross profit in the Healthcare Products Business increased to approximately HK$29.6 million for the year ended 31 March 2024 from approximately HK$12.2 million for the year ended 31 March 2023, representing an increase of approximately 142.6%[94]. - The Company's basic loss per share for the year ended 31 March 2024 was approximately HK4.41 cents, a significant decrease from approximately HK9.15 cents for the year ended 31 March 2023[101]. Operational Efficiency - The Group's knitwear product sales volume increased to approximately 5.7 million pieces for the Reporting Year, up from approximately 4.6 million pieces for the year ended March 31, 2023[29]. - The Group's total sales volume of finished knitwear products amounted to approximately 5.7 million pieces for the Reporting Year, an increase from approximately 4.6 million pieces for the year ended March 31, 2023[57]. - The average selling price per piece of menswear products increased from approximately HK$71.2 for the year ended 31 March 2023 to approximately HK$79.8 for the Reporting Year[62]. - The average selling price per piece of kidswear products increased from approximately HK$51.8 for the year ended 31 March 2023 to approximately HK$52.7 for the Reporting Year, despite the decrease in sales volume[34]. - Administrative expenses decreased to approximately HK$55.0 million for the year ended 31 March 2024 from approximately HK$63.1 million for the year ended 31 March 2023, representing a significant decrease of approximately 12.8%[73]. - Finance costs increased to approximately HK$7.1 million for the year ended 31 March 2024 from approximately HK$5.8 million for the year ended 31 March 2023[73]. Financial Position - The Group's current assets net value as of 31 March 2024 was approximately HK$6.9 million, down from approximately HK$101.5 million as of 31 March 2023, with a current ratio decreasing from approximately 1.9 to 1.0[78]. - The Group's gearing ratio was 0.08 as at 31 March 2024, up from 0.03 as at 31 March 2023[80]. - The Group has capital commitments of JPY50 million (approximately HK$2.6 million) as at 31 March 2024, unchanged from JPY50 million (approximately HK$2.9 million) as at 31 March 2023[85]. - The maximum liabilities of the Group under a legal action were in the amount of HK$5,280,000 as of 31 March 2024, with no other material contingent liabilities reported[85]. - The Group does not recommend the payment of a final dividend for the year ended 31 March 2024, consistent with the previous year[75]. - The Group's operations were generally financed through internally generated cash flows and bank borrowings, with plans to seek additional equity financing if necessary[75]. - The Group currently has no plans for material investments and capital assets[85]. - As of March 31, 2024, the Group's total staff costs amounted to approximately HK$54.3 million, a decrease from HK$55.1 million in 2023[89]. - The Group employed a total of 136 full-time employees as of March 31, 2024, unchanged from the previous year[89]. - The Group had net current assets of approximately HK$6.9 million as at 31 March 2024, down from HK$101.5 million as at 31 March 2023[103]. - The Group's current ratio decreased from approximately 1.9 as at 31 March 2023 to approximately 1.0 as at 31 March 2024, due to a significant increase in current liabilities by approximately 78.0%[103]. - The Group's debt-to-equity ratio was 0.08 as at 31 March 2024, compared to 0.03 as at 31 March 2023[106]. - The Group's unused bank financing rate was 63.1% as at 31 March 2024[106]. - The Group will continue to seek fundraising opportunities to strengthen its financial position[106]. Strategic Initiatives - The Group acquired Biotube Co., Ltd., a company engaged in physician-led clinical trials, which aligns with the Group's development areas and enhances its innovative research capabilities[12]. - The Group aims to provide a one-stop solution to academia, biotech ventures, and pharmaceutical companies in Japan and the PRC, leveraging its extensive knowledge in drug development support[19]. - The Group is coordinating industry resources to improve margins in its PRC specialized CRO business, which is becoming increasingly competitive[22]. - The Group's new strategies include enhancing its innovative research capabilities through acquisitions and improving operational margins through resource coordination[12][22]. - The Group has integrated and launched businesses in the healthcare segment, expanding its services to include comprehensive solutions in Japan[92]. - The Group aims to maintain good relationships with existing clients while proactively acquiring new customers by upgrading facilities and enhancing competitive strengths[91]. - The healthcare segment has expanded its services to include IRO and CRO business, enhancing new drug development support in Japan[135]. - The newly acquired subsidiary Biotube owns pipelines under ongoing investigator-initiated clinical trials, expected to create synergy effects for the Group[186]. - The Group aims to enhance necessary functions step by step towards creating a business co-creation platform to meet diverse needs in the healthcare industry[186]. Management and Governance - Mr. Shimada was appointed as the executive Director, Chairman, and CEO effective from November 1, 2023, bringing over 39 years of pharmaceutical experience[163]. - Mr. Miyano has over 32 years of experience in the domestic pharmaceutical industry in Japan and has been with EPS Japan since January 2002[166]. - Mr. Zhao, appointed as an executive Director from November 1, 2023, has over 32 years of experience in accounting, auditing, corporate finance, and mergers and acquisitions[166]. - Mr. Kusaba joined EPS Holdings in March 2022 and has extensive experience in business development and investment management[168]. - Mr. Yan Ping was appointed as a non-executive Director effective from November 1, 2023, with extensive experience in the biomedical industry in China[171]. - EPS Japan is a controlling shareholder of the Company, with Mr. Yan Hao indirectly owning approximately 71.51% of EPS Japan[171]. - The Company is focused on expanding its market presence and enhancing its product offerings through strategic appointments in senior management[166]. - The management team has a strong background in both domestic and international pharmaceutical markets, which is expected to drive future growth[166]. - The Company is committed to leveraging its leadership's extensive experience to explore new business opportunities and partnerships[171]. - The recent appointments are part of a broader strategy to strengthen governance and operational capabilities within the Company[166]. Environmental Commitment - The Group is committed to minimizing environmental impacts through energy saving and recycling initiatives[90]. - The Group promotes environmental protection by encouraging the use of electronic document processing to minimize paper use[131]. - The temperature of the air-conditioning system is set between 25˚C to 26˚C to enhance energy efficiency[131]. - The Group has implemented measures to maintain or reduce the intensity of air pollutants emissions[128]. - The total GHG emissions (Scope 1 and 2) increased by 31% to 67,353 kg CO2e compared to the previous reporting period[158]. - Scope 2 emissions rose by 32% to 65,992 kg CO2e, primarily due to changes in the reporting scope[158]. - Electricity consumption increased by 32% to 160,758 kWh, attributed to a change in the reporting scope[140]. - The intensity of GHG emissions per square meter increased by 14% to 32 kg CO2e/m²[158]. - The Group aims to reduce air pollutant emissions by 1-2% in the coming year[151]. - The Group's nitrogen oxides (NOx) emissions decreased by 13% to 0.33 kg[151]. - The Group generated no significant hazardous waste due to its business nature, reflecting a low environmental impact[161]. - The intensity of electricity consumption in Hong Kong offices increased by 16% to 73 kWh/m²[140]. - The Group's sulphur oxides (SOx) emissions remained stable at 0.01 kg[151]. - Non-hazardous waste for recycling purposes increased to 5.30 tonnes, a 221% increase compared to the previous year[122].

截至二零二四年三月三十一日止年度之 全年業績公告 EPS創健科技集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然公佈，本公司及 其附屬公司（統稱「本集團」）截至二零二四年三月三十一日止年度之綜合業績連同上一財 政年度之比較數字如下： （於開曼群島註冊成立之有限公司） （股份代號：3860） - 1 - 綜合損益表 截至二零二四年三月三十一日止年度 - 2 - - 3 - 流動資產 211,929 216,732 貿易及其他應付款項以及應計費用 12 52,084 34,347 合約負債 3,269 5,648 應付關聯公司款項 13 78,360 70,585 應付最終控股公司款項 13 45,739 318 應付非控股權益款項 13 11,759 – 租賃負債 2,606 2,564 應付稅項 3,878 1,722 銀行借貸 7,335 – 淨流動資產 6,899 101,548 | --- | --- | --- | --- | |------------------|-------|---------------------|---------------------| | | | | ...

Financial Performance - Revenue for the Reporting Period was approximately HK$357.8 million, an increase from HK$258.4 million in the same period last year, representing a growth of 38.5%[16] - Loss after taxation for the Reporting Period amounted to approximately HK$8.7 million, a decrease from a loss of HK$20.4 million in the previous year, indicating an improvement of 57.5%[16][21] - Basic loss per share for the Reporting Period was approximately 1.05 HK cents, based on a weighted average of 500,000,000 ordinary shares[16] - Gross profit for the Reporting Period was approximately HK$48.8 million, compared to HK$45.3 million in the previous year, reflecting a gross margin increase[21] - Other income for the Reporting Period was approximately HK$15.2 million, a significant increase from a loss of HK$1.9 million in the previous year[21] - Loss before taxation improved to approximately HK$8.2 million from HK$18.3 million in the previous year, showing a reduction of 55.2%[21] - Income tax expense for the Reporting Period was approximately HK$0.5 million, down from HK$2.1 million in the previous year[21] - For the six months ended September 30, 2023, the loss attributable to owners of the Company was HK$5,235,000, a significant improvement from a loss of HK$18,923,000 in the same period of 2022, representing a reduction of approximately 72.5%[23] - Total comprehensive expense for the period was HK$9,579,000, down from HK$21,253,000 in the prior year, indicating a decrease of about 55.1%[23] - Basic loss per share for the period attributable to owners of the Company improved to HK$0.09 from HK$1.05, reflecting a substantial decrease in loss per share of approximately 91.4%[23] Assets and Liabilities - Non-current assets increased to HK$120,958,000 as of September 30, 2023, compared to HK$10,762,000 as of March 31, 2023, showing a significant rise[25] - Current assets rose to HK$253,947,000 from HK$216,732,000, marking an increase of approximately 17.2%[25] - Current liabilities increased to HK$189,711,000 from HK$115,184,000, representing a rise of about 64.6%[25] - Net assets as of September 30, 2023, were HK$118,378,000, up from HK$91,644,000 as of March 31, 2023, indicating an increase of approximately 29.1%[27] - The Company reported an increase in inventories to HK$26,954,000 from HK$16,871,000, which is an increase of about 59.5%[25] - The amount due to a related party rose to HK$75,026,000 from HK$70,585,000, reflecting an increase of approximately 6.5%[25] - Trade debtors, net of loss allowance, increased to HK$66,426,000 as of 30 September 2023, up from HK$34,593,000 as of 31 March 2023, reflecting a 92.1% increase[95] - Trade payables rose to HK$64,473,000 as of 30 September 2023, compared to HK$22,406,000 as of 31 March 2023, marking a 187.5% increase[102] - As of 30 September 2023, the Group's total trade and other receivables amounted to HK$85,856,000, an increase from HK$58,220,000 as of 31 March 2023, representing a 47.5% growth[95] Cash Flow and Financing - The company generated HK$5,730,000 in cash from operations before working capital changes, a significant turnaround from cash used in operations of HK$19,416,000 in the previous year[35] - Net cash generated from operating activities was HK$5,233,000, compared to cash used of HK$20,215,000 in the same period last year[35] - The company reported a net increase in cash and cash equivalents of HK$1,553,000, contrasting with a decrease of HK$41,773,000 in the prior year[36] - The company invested HK$1,892,000 in property, plant, and equipment, compared to HK$76,000 in the same period of 2022[36] - Proceeds from bank borrowings amounted to HK$13,843,000, while repayments totaled HK$6,317,000, indicating active financing activities[36] - The company’s interest income increased to HK$760,000 from HK$31,000 in the previous year, reflecting improved financial management[36] Segment Performance - The Garment Business generated segment revenue of HK$274,964,000, while the Healthcare Products Business and IRO with CRO and In-house R&D Business contributed HK$65,060,000 and HK$17,805,000, respectively[52] - The Group reported a segment loss of HK$17,218,000 for the six months ended September 30, 2023, compared to a loss of HK$8,884,000 for the same period in 2022[52][55] - Revenue from external customers for the six months ended September 30, 2023, included HK$120,467,000 from the United States and HK$106,979,000 from Japan[63] - The Healthcare Products Business experienced a segment loss of HK$369,000, while the IRO with CRO and In-house R&D Business reported a significant loss of HK$26,661,000[52] - The Group recorded revenue of approximately HK$17.8 million for the Reporting Period in the specialized CRO business, representing an increase of approximately 141.3% compared to HK$7.4 million for the six months ended 30 September 2022[150] Expenses - Selling and distribution expenses increased to HK$25.5 million from HK$21.5 million, indicating a rise of 18.6%[21] - Administrative expenses were slightly higher at HK$32.1 million compared to HK$31.6 million in the previous year[21] - Research and development expenses for the six months ended 30 September 2023 amounted to HK$11,408,000, an increase from HK$5,412,000 in the previous year, reflecting a growth of approximately 110.5%[80] - Staff costs, including directors' remuneration, rose to HK$43,003,000 for the six months ended 30 September 2023, compared to HK$25,517,000 in the previous year, marking an increase of approximately 68.2%[80] - Selling and distribution expenses increased by approximately HK$4.0 million or 18.2% to approximately HK$25.5 million, primarily due to rising transportation costs[186] - Administrative expenses rose by approximately HK$0.5 million or 1.6% to approximately HK$32.1 million, mainly due to increased staff costs and legal fees[191] Dividends - The Board does not recommend the payment of an interim dividend for the Reporting Period[16] - No dividends were paid, declared, or proposed during both interim periods, with the Board not recommending any payment of interim dividend for the current interim period[75] Acquisitions and Investments - The company acquired 65% of R&E Corporation Limited for HK$56.16 million, completed on May 23, 2023[108] - The identifiable net assets acquired amounted to HK$15.76 million, with goodwill arising from the acquisition at HK$19.92 million[111] - The acquisition of R&E Corporation Limited is part of the company's strategy to expand into the Japanese health food market[108] - The Limited Partnership established in Japan aims to invest in start-ups and emerging companies with high growth potential in healthcare, intelligent manufacturing, technology, and consumer services[93] Strategic Focus - The Group is focusing on anti-obesity and anti-diabetes therapies using brown adipocytes induction technology, and is collaborating with a major university in Japan on a treatment for Lower Extremity Artery Diseases (LEAD)[149] - The Group aims to provide a one-stop solution for drug development support, leveraging its knowledge and experience in the IRO and CRO services[142] - The IRO business is expected to create synergies for the expansion of the In-House R&D and Healthcare Products Business segments[147] - The Group's sales teams are actively expanding client bases and exploring new manufacturing sources and product development to maintain profitable margins in the Garment Business[134] - Economic challenges such as rising interest rates and inflation continue to impact the Group's business operations[134]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：3860） 截至二零二三年九月三十日止六個月 之中期業績公告 財務摘要 － 報告期內錄得收益約357.8百萬港元； － 期內之除稅後虧損為約8.7百萬港元； － 根據本公司500,000,000股本公司普通股加權平均數計算，期內之每股基本虧損為 約1.05港仙；及 － 董事會並不建議派付報告期內之中期股息。 ...

Revenue and Profit Performance - The apparel segment recorded revenue of approximately HKD 381.5 million, a decrease of about 10.2% compared to HKD 424.6 million for the year ended March 31, 2022[11]. - The gross profit for the apparel segment was approximately HKD 61.8 million, slightly down from HKD 62.5 million for the previous year[11]. - The healthcare products segment generated revenue of approximately HKD 55.8 million, a decrease of about 29.8% from HKD 79.5 million in the previous year[23]. - The gross profit for the healthcare products segment was approximately HKD 12.2 million, down from HKD 18.2 million, attributed to decreased procurement orders from a major client in Japan and the depreciation of the yen[23]. - The internal R&D segment recorded revenue of approximately HKD 15.6 million, a slight decrease of about 1.3% from HKD 15.8 million in the previous year[29]. - The total revenue decreased from approximately HKD 424.6 million to HKD 381.5 million, a reduction of about HKD 43.1 million, primarily due to a significant decrease in procurement orders from a major client based in Japan[34]. - Women's apparel revenue decreased from approximately HKD 323.6 million to HKD 298.8 million, a decline of about HKD 24.8 million (7.7%) due to a drop in sales volume from approximately 4.1 million units to 3.3 million units, despite an increase in average selling price from HKD 78.3 to HKD 89.3[42]. - Men's apparel revenue increased from approximately HKD 61.9 million to HKD 69 million, an increase of about HKD 7.1 million (11.5%), primarily due to an increase in average selling price from HKD 64.2 to HKD 71.2[42]. - Children's apparel revenue significantly decreased from approximately HKD 39.1 million to HKD 13.7 million, a decline of about HKD 25.5 million (65.1%), attributed to a drop in sales volume from approximately 0.7 million units to 0.3 million units and a decrease in average selling price from HKD 58.1 to HKD 51.8[43]. - Revenue from health products decreased from approximately HKD 79.5 million to HKD 55.8 million, a decline of about HKD 23.7 million (29.8%), mainly due to reduced procurement orders from major Japanese clients[44]. Acquisitions and Business Expansion - The company is focusing on enhancing its healthcare product business and innovation research organization (IRO) through acquisitions during the reporting period[5]. - The company has acquired three Chinese companies engaged in clinical trial services and one company in Japan for procurement and distribution of healthcare products[19]. - The company completed the acquisition of 100% of EP Trading Limited in December 2022, enhancing its distribution capabilities for healthcare products[23]. - The group completed the acquisition of three Chinese equity companies for a total consideration of approximately RMB 2.85 million (approximately HKD 3.24 million) on September 20, 2022[78]. - The acquisition of EP Trading Co., Ltd. was completed for a total consideration of approximately JPY 99.4 million (approximately HKD 5.6 million) on December 7, 2022[79]. - The group acquired 65% of R&E Corporation Limited for a total consideration of approximately HKD 56.16 million, completed on May 23, 2023[83]. - The IRO business is expected to provide synergies for the expansion of internal R&D and healthcare products[27]. - The company expects to leverage its acquisitions for future growth and market expansion strategies[140]. Financial Position and Liabilities - The total comprehensive expenses attributable to the company's owners increased to approximately HKD 45.4 million, up from HKD 20.6 million, mainly due to increased research and administrative expenses related to new drug development[33]. - As of March 31, 2023, the group's current assets amounted to approximately HKD 101.5 million, a decrease of about 23.9% compared to HKD 202.4 million on March 31, 2022[68]. - The current ratio declined from approximately 3.5 on March 31, 2022, to about 1.9 on March 31, 2023, primarily due to a significant increase in current liabilities by approximately 40%[68]. - The group's debt-to-equity ratio increased from 1.12 on March 31, 2022, to 1.48 on March 31, 2023, reflecting the total loans and borrowings[68]. - The total liabilities as of March 31, 2023, were 82,288 thousand HKD, with trade and other payables amounting to 36,451 thousand HKD[143]. - Current liabilities increased to HKD 115,184 thousand from HKD 82,288 thousand, marking an increase of approximately 40.1%[126]. - The company’s total equity as of March 31, 2023, was HKD 91,644 thousand, compared to HKD 139,864 thousand, indicating a decrease of about 34.5%[128]. - The company’s retained earnings showed a cumulative loss of HKD 27,015 thousand as of March 31, 2023, compared to a loss of HKD 34 thousand in the previous year[128]. Employee and Operational Insights - The total employee costs for the year ended March 31, 2023, were approximately HKD 55.1 million, compared to HKD 38.8 million for the previous year, indicating a significant increase in personnel expenses[92]. - As of March 31, 2023, the group employed a total of 112 employees, with 111 being full-time and 1 part-time[199]. - The group adheres to local labor laws for employee annual leave and benefits, ensuring fair compensation based on individual performance[196]. - The group emphasizes a transparent and fair recruitment system, providing equal opportunities and a discrimination-free workplace[195]. - The management compensation is linked to the group's operational performance, incentivizing management based on the company's success[196]. - The group is committed to eliminating workplace bias and discrimination based on gender, marital status, disability, and family status[195]. - The employee distribution by gender shows 88 males and 24 females, indicating a male-dominated workforce[199]. - The group has implemented effective measures to protect employee rights and ensure compliance with anti-discrimination laws[195]. Future Outlook and Strategic Initiatives - The company maintains a cautiously optimistic outlook, investing in product design and development, including healthcare apparel products[12]. - The company aims to create a business co-creation platform to meet the diverse needs of the healthcare industry between China and Japan[12]. - The group is cautiously optimistic about the future, planning to invest in product design and development, including health apparel, to promote a healthy lifestyle[98]. - The group plans to simplify its organizational structure and operational processes to save costs and enhance competitiveness[98]. - The group will continue to explore opportunities for business diversification while considering market uncertainties[110]. - The growth of the apparel supply chain management services is expected to be driven by increased disposable income and economic recovery globally[98]. Environmental and Social Responsibility - The group aims to reduce the negative environmental impact of daily operations through energy-saving and resource recycling methods, complying with all relevant environmental laws and regulations as of March 31, 2023[94]. - The company has recognized potential financial losses due to extreme weather events, which may lead to increased operational costs and delayed deliveries[186]. - The company has implemented various measures to prevent and mitigate the negative impacts of extreme weather[187]. - The company aims to support harmonious social development and establish mutually beneficial relationships with stakeholders[194]. - The group is dedicated to sustainable development while achieving economic goals, reflecting its social responsibility[195].